Scientific definition of exozymes featured as cover story in GEN Biotechnology, freely available as an Open Access paper The author team introduces the terms ‘exozymes' to bring clarity to the rapidly evolving field of cell-free biomanufacturing—a biomanufacturing method to produce chemicals without relying on living cells like bacteria or yeast The paper features co-authors from multiple institutions such as The National Renewable Laboratory (NREL), UCLA, Caltech, University of Colorado Boulder, Sepia Biosciences, as well as the venture studio, Ferment  The authors intend the terms to be freely available for use by the broader scientific community, and no trademarks have been filed Mon

Monrovia, CA, April 10, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced its latest initiative - BioClick - a pioneering concept designed to enhance and accelerate the engineering of enzymes for advanced chemical reactions. Funded in part by a $300K grant from the National Institutes of Health (NIH), this project has the potential to revolutionize how medicines and other bio-based compounds are created. At the heart of BioClick is a focus on group transfer reactions, a class of biochemical reactions that allow enzym

Expanded leadership team as eXoZymes ramps up commercial growth Damien Perriman brings more than two decades of experience in successfully developing and commercializing novel biotechnologies Focus on developing commercial opportunities, spin-outs, joint-ventures, and licensing deals with future partners Monrovia, CA, April 02, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - announced the appointment of Damien Perriman to a newly created role as Chief Commercial Officer (CCO). Perriman brings more than two decades of experience i

Management to Host Conference Call Today at 4:30PM Eastern Monrovia, CA, April 02, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential nutraceuticals, medicines, biofuels, and other valuable chemicals - provides an update on operations through the fiscal year ended December 31, 2024. Michael Heltzen, CEO of eXoZymes, states, "As a pre-revenue company, what's important for us is that we keep progressing towards our specific milestones and value infection points, like getting to our first commercial applications via spin-outs, joint-ventures, and licensing deals as the drivers

Monrovia, CA , March 26, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ:EXOZ) ["eXoZymes"] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - plans to host a webinar on Wednesday, April 2, 2025 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full year 2024. A press release detailing these results will be issued prior to the call. Michael Heltzen, CEO of eXoZymes will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period. Investors can pre-regi

Monrovia, CA, Feb. 21, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ:EXOZ, formerly Invizyne Technologies)) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - and MDB Capital Holdings (NASDAQ:MDBH) - a premier venture platform for breakthrough technology companies - today announced key leadership changes within the eXoZymes board of directors. Mo Hayat has transitioned out of his roles as Chairman of the Board and President of eXoZymes, to focus on new MDB Capital ventures. Edgardo Rayo will join the board on behalf of MDB Capital, making it a full circle moment, as he was the MDB Capital team member who disco

Monrovia, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- eXoZymes, Inc. (NASDAQ:EXOZ) ("eXoZymes") – a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels – today announced that CEO Michael Heltzen will be joined by eXoZymes team members to ring the Nasdaq Stock Market ("Nasdaq") closing bell on Wednesday, February 19, 2025. This comes following a successful initial public offering of common stock at $8 per share, which closed on November 14, 2024. "Our team is thrilled to be ringing the closing bell to commemorate both our initial public offering and our significant progress towards establishing that after synthetic biology (